T1	PROC 46 73	Estudio sin enmascaramiento
T2	Neg_cue 54 57	sin
T3	Negated 58 73	enmascaramiento
T4	Date 74 87	a largo plazo
T5	PROC 93 127	evaluar la seguridad y la eficacia
T6	CHEM 131 143	donidalorsén
T7	PROC 149 173	tratamiento profiláctico
#1	AnnotatorNotes T7	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T8	DISO 178 200	angioedema hereditario
#2	AnnotatorNotes T8	C0019243; Angioedemas, Hereditary; Disease or Syndrome
T9	DISO 202 205	AEH
#3	AnnotatorNotes T9	C0019243; Angioedemas, Hereditary; Disease or Syndrome
T10	DISO 230 249	Enfermedad genética
#4	AnnotatorNotes T10	C0019247; Hereditary Diseases; Disease or Syndrome
T11	DISO 284 317	edemas subcutáneos y/o submucosos
T12	Duration 318 330	transitorios
T13	DISO 361 370	hinchazón
#5	AnnotatorNotes T13	C0038999; Swelling; Finding
T14	DISO 375 390	dolor abdominal
#6	AnnotatorNotes T14	C0000737; Abdominal Pain; Sign or Symptom
T15	DISO 417 439	angioedema hereditario
#7	AnnotatorNotes T15	C0019243; Angioedemas, Hereditary; Disease or Syndrome
T16	DISO 441 444	AEH
#8	AnnotatorNotes T16	C0019243; Angioedemas, Hereditary; Disease or Syndrome
T17	LIVB 479 492	participantes
T18	LIVB 519 533	representantes
#9	AnnotatorNotes T18	C0600419; Patient Agent; Group | C1708966; Medical Equipment Company Technician or Representative; Professional or Occupational Group
T19	LIVB 568 588	padre(s)/tutor legal
T20	PROC 627 651	consentimiento informado
#10	AnnotatorNotes T20	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T21	PROC 653 656	ICF
T22	LIVB 688 701	participantes
T23	CHEM 752 775	medicamento(s) agudo(s)
T24	CHEM 785 819	concentrado de C1-INH recombinante
T25	CHEM 822 840	derivado de plasma
T26	CHEM 846 893	antagonista del receptor de bradicinina (BK) 2)
T27	PROC 899 905	tratar
T28	DISO 910 931	ataques de angioedema
T29	LIVB 937 950	participantes
T30	PROC 1035 1088	estudio de índice aleatorizado controlado con placebo
T31	Date 1096 1108	la semana 25
T32	LIVB 1111 1124	participantes
T33	PROC 1188 1197	protocolo
#11	AnnotatorNotes T33	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T34	LIVB 1251 1264	Participantes
T35	Neg_cue 1273 1275	no
T36	Negated 1276 1303	previamente en donidalorsen
T37	LIVB 1322 1335	participantes
T38	Age 1348 1357	≥ 12 años
T39	PROC 1376 1400	consentimiento informado
#12	AnnotatorNotes T39	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T40	LIVB 1447 1460	participantes
T41	PROC 1476 1487	diagnóstico
#13	AnnotatorNotes T41	C0011900; Diagnosis; Diagnostic Procedure
T42	DISO 1503 1508	HAE-1
T43	DISO 1509 1514	HAE-2
T44	LIVB 1522 1535	participantes
T45	Dose 1551 1568	una dosis estable
T46	Duration 1569 1582	(≥ 12 semanas
T47	PROC 1587 1611	tratamiento profiláctico
#14	AnnotatorNotes T47	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T48	CHEM 1616 1627	lanadelumab
T49	CHEM 1630 1642	berotralstat
T50	CHEM 1645 1675	inhibidor de la esterasa SC C1
T51	Route 1670 1672	SC
T52	CHEM 1844 1854	medicación
#15	AnnotatorNotes T52	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T53	LIVB 1855 1868	Participantes
T54	PROC 1880 1903	Diagnóstico concurrente
T55	DISO 1930 1940	angioedema
#16	AnnotatorNotes T55	C0002994; Angioedema; Pathologic Function
T56	DISO 1965 1996	angioedema idiopático adquirido
T57	DISO 1999 2002	AEH
#17	AnnotatorNotes T57	C0019243; Angioedemas, Hereditary; Disease or Syndrome
T58	PROC 2007 2013	C1-INH
T59	DISO 2044 2056	AEH tipo III
T60	CHEM 2092 2102	andrógenos
#18	AnnotatorNotes T60	C0002844; Androgens; Hormone · Pharmacologic Substance
T61	PROC 2119 2129	profilaxis
#19	AnnotatorNotes T61	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T62	CHEM 2134 2151	ácido tranexámico
#20	AnnotatorNotes T62	C0040613; tranexamic acid; Organic Chemical · Pharmacologic Substance
T63	PROC 2157 2165	prevenir
#21	AnnotatorNotes T63	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T64	DISO 2166 2187	ataques de angioedema
T65	DISO 2198 2209	anormalidad
#22	AnnotatorNotes T65	C1704258; Abnormality; Finding
T66	PROC 2244 2279	valores de laboratorio de detección
T67	DISO 2283 2300	Neoplasia maligna
#23	AnnotatorNotes T67	C0006826; Malignant Neoplasms; Neoplastic Process | C1306459; Primary malignant neoplasm; Neoplastic Process
T68	Duration 2311 2321	los 5 años
T69	PROC 2339 2348	detección
#24	AnnotatorNotes T69	C1511790; Detection; Therapeutic or Preventive Procedure
T70	Neg_cue 2350 2364	a excepción de
T71	DISO 2369 2397	cánceres de piel no melanoma
#25	AnnotatorNotes T71	C0699893; Skin carcinoma; Neoplastic Process
T72	Negated 2369 2397	cánceres de piel no melanoma
T73	DISO 2402 2437	carcinoma in situ de cuello uterino
T74	Negated 2402 2437	carcinoma in situ de cuello uterino
T75	DISO 2442 2474	carcinoma ductal de mama in situ
T76	Negated 2442 2474	carcinoma ductal de mama in situ
T77	DISO 2480 2501	carcinoma de próstata
#26	AnnotatorNotes T77	C0600139; Prostate carcinoma; Neoplastic Process
T78	Negated 2480 2501	carcinoma de próstata
T79	PROC 2527 2534	tratado
T80	DISO 2549 2566	Hipersensibilidad
#27	AnnotatorNotes T80	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding | C0585186; Cutaneous hypersensitivity; Disease or Syndrome
T81	CHEM 2570 2586	principio activo
T82	CHEM 2588 2600	donidalorsen
T83	CHEM 2620 2631	excipientes
#28	AnnotatorNotes T83	C0015237; Pharmaceutical Excipient; Biomedical or Dental Material
T84	PROC 2635 2646	Tratamiento
#29	AnnotatorNotes T84	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T85	CHEM 2656 2680	fármaco en investigación
T86	Neg_cue 2682 2684	no
T87	CHEM 2685 2700	oligonucleótido
#30	AnnotatorNotes T87	C0028953; Oligonucleotides; Nucleic Acid, Nucleoside, or Nucleotide
T88	Negated 2685 2700	oligonucleótido
T89	CHEM 2704 2720	agente biológico
#31	AnnotatorNotes T89	C0005515; Biological Factors; Biologically Active Substance
T90	Duration 2736 2741	1 mes
T91	Duration 2763 2774	5 semividas
T92	CHEM 2779 2802	agente en investigación
T93	Date 2838 2846	reciente
T94	DISO 2849 2881	abuso actual de drogas o alcohol
T95	Date 2855 2861	actual
T96	LIVB 2921 2933	donidalorsen
T97	CHEM 2979 2991	medicamentos
#32	AnnotatorNotes T97	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0304228; Proprietary drug, NOS; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T98	CHEM 2993 3046	Inhibidores de la enzima convertidora de angiotensina
#33	AnnotatorNotes T98	C0003015; Angiotensin-Converting Enzyme Inhibitors; Pharmacologic Substance
T99	CHEM 3048 3051	ECA
#34	AnnotatorNotes T99	C0022709; Peptidyl-Dipeptidase A; Amino Acid, Peptide, or Protein · Enzyme · Immunologic Factor
T100	CHEM 3065 3076	medicamento
#35	AnnotatorNotes T100	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0304228; Proprietary drug, NOS; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T101	CHEM 3090 3099	estrógeno
#36	AnnotatorNotes T101	C0014939; estrogens; Hormone · Organic Chemical · Pharmacologic Substance
T102	PHYS 3104 3113	absorción
T103	Route 3114 3123	sistémica
T104	CHEM 3124 3140	Oligonucleótidos
#37	AnnotatorNotes T104	C0028953; Oligonucleotides; Nucleic Acid, Nucleoside, or Nucleotide
T105	CHEM 3154 3197	ácido ribonucleico de interferencia pequeño
T106	CHEM 3199 3204	siRNA
T107	Duration 3217 3228	los 4 meses
T108	Dose 3270 3273	una
T109	Dose 3274 3285	dosis única
T110	Duration 3299 3311	los 12 meses
T111	Dose 3356 3371	dosis múltiples
T112	Neg_cue 3388 3390	no
T113	CHEM 3407 3414	vacunas
#38	AnnotatorNotes T113	C0042210; Vaccines; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T114	Negated 3407 3414	vacunas
